News

Public · Published

Weekly Recap: Q3 gains and Qelbree sales, prescription growth

Supernus Pharmaceuticals reported third-quarter 2026 revenue up 18% to $226.8 million and profit of $20.9 million, compared with a loss a year earlier. Qelbree sales rose 12% and prescriptions grew 18%; the company raised its 2026 revenue outlook to $875–$900 million and described progress on three drug trials.

Published:

Updated:

What happened

Supernus Pharmaceuticals reported third-quarter 2026 revenue up 18% to $226.8 million and profit of $20.9 million, compared with a loss a year earlier. Qelbree sales rose 12% and prescriptions grew 18%; the company raised its 2026 revenue outlook to $875–$900 million and described progress on three drug trials.

Confirmed

Global impact / market context

Higher Qelbree sales and prescription growth provide evidence of stronger demand for an existing product, while the raised outlook signals management expects revenue to remain higher. Trial progress could create future product opportunities, but the candidates are still being tested and their commercial value is uncertain.

Analyst inference

The update combines current business results with early-stage drug development. Revenue and profit reflect sales already made, whereas the trial programs do not yet establish that the candidates will work or reach patients. The outlook therefore depends more directly on commercial performance than on unapproved drugs.

Analyst inference

What to watch

  1. Track whether Qelbree sales and prescriptions continue growing; sustained demand would support revenue, while a slowdown could make the raised full-year outlook harder to achieve. Analyst inference
  2. Watch for updates on the ongoing Phase 2b trials of SPN-817 and SPN-820, and whether Supernus starts SPN-443’s Phase 1 trial by the end of 2026. Confirmed
  3. Compare later revenue with the $875–$900 million 2026 outlook; results below that range could weaken confidence in expected sales growth and the company’s return to profit. Analyst inference

Evidence

  • Original source link unavailable